Nurix Therapeutics Inc 2024年度报告

NURIX THERAPEUTICS, INC. Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesxNoo Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesoNox Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. YesxNoo Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe Registrant was required to submit such files). YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.o Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNox Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) bythe registered public accounting firm that prepared or issued its audit report.x The aggregate market value of the common stock held by non-affiliates of the Registrant, based on the closing price of theRegistrant’s common stock on May 31, 2024 (the last business day of the Registrant’s most recently completed second fiscalquarter) as reported by the Nasdaq Global Market on such date was approximately $995.9 million. This calculation does not reflect adetermination that certain persons are affiliates of the Registrant for any other purpose.As of January 24, 2025, the Registrant had 75,886,817 shares of common stock, $0.001 par value per share, outstanding. Certain sections of the Registrant’s definitive Proxy Statement to be filed in connection with the Registrant’s 2025 Annual Meeting ofStockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such definitive ProxyStatement will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days of the Registrant’sfiscal year ended November 30, 2024. TABLE OF CONTENTS Page PART I Item 1.Business4Item 1A.Risk Factors50Item 1B.Unresolved Staff Comments107Item 1C.Cybersecurity107Item 2.Properties108Item 3.Legal Proceedings109Item 4.Mine Safety Disclosures109 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities110Item 6.[Reserved]111Item 7.Management’s Discussion and Analysis of Financial Condition and Results ofOperations112Item 7A.Quantitative and Qualitative Disclosures About Market Risk125Item 8.Financial Statements and Supplementary Data126Item 9.Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure158Item 9A.Controls and Procedures158Item 9B.Other Information159Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspection159 PART III Item 10.Directors, Executive Officers and Corporate Governance160Item 11.Executive Compensation160Item 12.Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters160Item 13.Certain Relationships and Related Transactions, and Director Independence160 PART IV Item 15.Exhibits and Financial Statement Schedules161Item 16.Form 10-K Summary165Signatures166 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995. All statements contained in this Annual Report on Form10-K other t